Skip to main content
. 2017 Feb 8;8(14):22716–22729. doi: 10.18632/oncotarget.15187

Figure 1. MiR-1 expression and regulation of IL11 in human endometrial cancer and cell lines.

Figure 1

(A) MiR-1 expression was quantified in G1, 2, or 3 human endometrial cancer tissue, or benign (B) endometrium by real-time RT-PCR normalized to snU6 (n = 10/group) and in (B) normal proliferative phase endometrial epithelial cells (n = 4), or human endometrial cancer cell lines; Ishikawa, HEC-1A, RL95 and AN3CA derived from grade 1, 2, or 3 human endometrial cancers respectively, normalized to 18 s (n = 3 passages/cell line). (C) Transfection efficiency of miR-1 mimic after 72 h in HEC1A and AN3CA cells was confirmed by quantitative real time RT-PCR. (D) 72 h post-transfection, the effect of miR-1 mimic or scr control on cell viability was determined by MTT assay (n = 3) and on (E) IL11, IL11Rα, or gp130 gene expression normalized to 18 s (n = 3). (F) AN3CA cells transfected with miR-1 mimic or scr control ± IL11 (100 ng/ml) were used in xCELLigence real time proliferation assays performed in triplicate (n = 3). Data are mean ± SEM. (C–E) t-test, *p < 0.05, **p < 0.01 (F) ANOVA, **p < 0.01.